Tests 4D-150 eye injection against aflibercept in age-related macular degeneration
Compares one 4D-150 eye injection with aflibercept in adults with wet macular degeneration.
Plain-language title generated from the registry record
Registry title: Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Key facts
- Where
- Amarillo, Austin, Baltimore, Bloomfield, Bluffton, Campbell, Carmel, Cary, Cincinnati, Colorado Springs, Dallas, Denver, Durango, Elmhurst, Erie, Eugene, Fullerton, Grand Rapids, Hagerstown, Hudson, Johnson City, Lakeland, Liverpool, Lynchburg, Mountain View, Mt. Pleasant, Nashville, New York, Oak Forest, Oak Park, Orlando, Pensacola, Portland, Rapid City, Reno, Sacramento, Salt Lake City, San Francisco, San Marcos, Sandy Springs, Scottsdale, Silverdale, Springfield, St Louis, St. Petersburg, Stuart, Sun City, Tampa, Tucson, Tyler, Wake Forest, Walnut Creek, Wausau, West Columbia, West Monroe, Westbury, and Willow Park, United StatesSee the 60 sites
- Phase
- Phase 3
Where in United States
- Southwest Retina Specialist - Panhandle Eye group, LLPAmarillo, United StatesNo longer taking part
- Austin Clinical ResearchAustin, United StatesNo longer taking part
- The Retina Care CenterBaltimore, United StatesNo longer taking part
- Envision Ocular, LLCBloomfield, United StatesNo longer taking part
- Charleston Neuroscience Institute, LLCBluffton, United StatesNo longer taking part
- Retinal Diagnostic CenterCampbell, United StatesNo longer taking part
- Retina Partners Midwest, PCCarmel, United StatesNo longer taking part
- North Carolina Retina AssociatesCary, United StatesNo longer taking part
- Cincinnati Eye InstituteCincinnati, United StatesNo longer taking part
- Retina Consultants of Southern Colorado P.C.Colorado Springs, United StatesNo longer taking part
- Texas Retina AssociateDallas, United StatesNo longer taking part
- Retina Specialists of ColoradoDenver, United StatesNo longer taking part
- Southwest Retina ConsultantsDurango, United StatesNo longer taking part
- Retina Associates, Ltd.Elmhurst, United StatesNo longer taking part
- Erie Retina ResearchErie, United StatesNo longer taking part
- Verum Research, LLCEugene, United StatesNo longer taking part
- Retina Consultants of Orange CountyFullerton, United StatesNo longer taking part
- Foundation for Vision ResearchGrand Rapids, United StatesNo longer taking part
- Cumberland Valley Retina ConsultantsHagerstown, United StatesNo longer taking part
- Mid Atlantic Retina SpecialistsHagerstown, United StatesNo longer taking part
- ClearVista Clinical ResearchHudson, United StatesNo longer taking part
- Southeastern Retina AssociatesJohnson City, United StatesNo longer taking part
- Florida Retina ConsultantsLakeland, United StatesNo longer taking part
- Retina Vitreous Surgeons of CNY, PCLiverpool, United StatesNo longer taking part
- Piedmont Eye CenterLynchburg, United StatesNo longer taking part
- Northern California Retina Vitreous AssociatesMountain View, United StatesNo longer taking part
- Carolina Eyecare PhysiciansMt. Pleasant, United StatesNo longer taking part
- Tennessee Retina, PCNashville, United StatesNo longer taking part
- New York Presbyterian Hospital-Columbia University Medical CenterNew York, United StatesNo longer taking part
- University Retina and Macula Associates, PCOak Forest, United StatesNo longer taking part
- Illinois Retina AssociatesOak Park, United StatesNo longer taking part
- Florida Retina InstituteOrlando, United StatesNo longer taking part
- Retina Specialty InstitutePensacola, United StatesNo longer taking part
- EyeHealth NorthwestPortland, United StatesNo longer taking part
- Black Hills Regional Eye InstituteRapid City, United StatesNo longer taking part
- Sierra Eye AssociatesReno, United StatesNo longer taking part
- Retinal Consultants Medical GroupSacramento, United StatesNo longer taking part
- Retinal Consultants Medical Group, Inc.Sacramento, United StatesNo longer taking part
- Rocky Mountain Retina ConsultantsSalt Lake City, United StatesNo longer taking part
- West Coast Retina Medical GroupSan Francisco, United StatesNo longer taking part
- Austin Retina AssociatesSan Marcos, United StatesNo longer taking part
- Thomas Eye GroupSandy Springs, United StatesNo longer taking part
- Research Network ArizonaScottsdale, United StatesNo longer taking part
- Pacific Northwest RetinaSilverdale, United StatesNo longer taking part
- New England Retina ConsultantsSpringfield, United StatesNo longer taking part
- Springfield ClinicSpringfield, United StatesNo longer taking part
- The Retina InstituteSt Louis, United StatesNo longer taking part
- Retina Vitreous Associates of FloridaSt. Petersburg, United StatesNo longer taking part
- East Florida Eye InstituteStuart, United StatesNo longer taking part
- Barnet Dulaney Perkins Eye CenterSun City, United StatesNo longer taking part
- Retina Vitreous Associates of FloridaTampa, United StatesNo longer taking part
- Retina AssociatesTucson, United StatesNo longer taking part
- Tyler Retina ConsultantsTyler, United StatesNo longer taking part
- North Carolina Retina AssociatesWake Forest, United StatesNo longer taking part
- Bay Area Retina AssociatesWalnut Creek, United StatesNo longer taking part
- Eye Clinic of WisconsinWausau, United StatesNo longer taking part
- Palmetto Retina CenterWest Columbia, United StatesNo longer taking part
- Haik Humble Eye CenterWest Monroe, United StatesNo longer taking part
- Vitreoretinal Consultants of NYWestbury, United StatesNo longer taking part
- Strategic Clinical ResearchWillow Park, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- 4D Molecular Therapeutics
- Trial code
- NCT07064759
- Record updated
- 19 October 2026
- Original description
This Phase 3 study is evaluating the safety and efficacy of 4D-150 versus aflibercept in participants with neovascular age-related macular degeneration (nAMD). Enrollment in the primary global cohort has been completed; Study centers in Japan remain open for enrollment for the Japan cohort.Read full original descriptionShow less
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults With Macular Neovascularization Secondary to Age-Related Macular Degeneration
This Phase 3 study is evaluating the safety and efficacy of 4D-150 versus aflibercept in participants with neovascular age-related macular degeneration (nAMD). Enrollment in the primary global cohort has been completed; Study centers in Japan remain open for enrollment for the Japan cohort.
Inclusion: ≥50 years of age at time of consent; MNV secondary to nAMD with IVT anti-VEGF treatment history in the study eye, defined as EITHER:; Treatment naïve, i.e. no prior IVT anti-VEGF therapy OR; Previously treated with no more than 4 IVT anti-VEGF injections due to nAMD and received diagnosis of nAMD no more than 6 months prior to the Screening Visit AND documented evidence of anatomical improvement and visual stability/improvement in response to previous IVT anti-VEGF treatment, as determined by the Investigator; Active subfoveal MNV or juxtafoveal/ extrafoveal MNV with a subfoveal component (where activity is defined as evidence of SRF, IRF, subretinal hyperreflective material, or leakage) identified by fluorescein angiography (FA) or spectral domain optical coherence tomography (SD-OCT) , in the study eye, at the Screening Visit confirmed by the Reading Center; Demonstrated clinical response to aflibercept and functional stability in the study eye as confirmed by the Reading Center; BCVA between 25 and 78 ETDRS letters, inclusive (20/320-20/32 Snellen equivalent) in the study eye at the Screening Visit; CST less than or equal to 500 microns in the study eye at screening visit, confirmed by the central reading center.
Exclusion: Any prior or concomitant treatment for MNV or vitreomacular-interface abnormalities, other than allowed prior IVT anti-VEGF in the study eye; Systemic Conditions and Considerations:; Major illness or major surgical procedure in the 28 days prior to the Screening Visit; Ocular Conditions:; MNV due to causes other than nAMD in either eye (Fibrosis, atrophy, or subretinal hemorrhage in the foveal central subfield (1 mm diameter); History of retinal detachment in the study eye; History of or presence of active inflammation in either eye; Glaucoma or intraocular hypertension requiring more than 2 topical medications for control; Ocular Treatments/Interventions:; Acute coronary syndrome, myocardial infarction or coronary artery revascularization, cerebrovascular accident, transient ischemic attack within 6 months of the Screening Visit; History of autoimmune condition that may predispose to the development of uveitis; Uncontrolled blood pressure.